

Appln. No. 10/041,600

Amd. dated February 7, 2005

Reply to Office Action of October 22, 2004

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1(Original). A tumor cell transfected with a DNA coding for at least one MHC class II ligand selected from the group consisting of CD4, LAG-3, and derivatives thereof.

Claim 2 (Cancelled).

3(Currently amended). A process for preparing the tumor cell of claim 1, comprising:

removing tumor cells from a patient;

transfecting a tumor cell with a DNA coding for at least one MHC class II ligand selected from the group consisting of CD4, LAG-3, and derivatives thereof; and

recovering the transfected tumor cell.

Claims 4-6 (Cancelled).

7(Currently amended). A pharmaceutical composition for treating ~~or preventing~~ pathological conditions involving an antigen specific immune response, comprising a pharmaceutically acceptable vehicle and cells transfected with DNA coding for at least one MHC class II ligand selected from the group consisting

Appln. No. 10/041,600

Amd. dated February 7, 2005

Reply to Office Action of October 22, 2004

of CD4 and LAG-3 and expressing said at least one MHC class II
ligand.

Claim 8 (Cancelled).

9(Currently amended). A method for treating ~~or~~
~~preventing~~ a pathological condition involving antigen specific T-
cell mediated immune response, comprising administering the
pharmaceutical composition of claim 7 to a subject in need
thereof.